Navigation Links
TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease
Date:12/9/2009

WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease. Three times as many newly diagnosed second-line patients received a TNF-alpha inhibitor versus one year ago (15.2 percent versus 5.6 percent). This boost is due in part to physicians' increased prescribing of Centocor Ortho Biotech's Remicade as a second- or third-line therapy for newly diagnosed patients.

"Our analysis of patient-level claims data shows that both Remicade and Abbott's Humira contributed to the increased uptake of TNF-alpha inhibitors in newly diagnosed patients. However, Remicade outpaces Humira substantially in second- and third-line treatment for these patients," stated Madhuri Borde, Ph.D., product director at Decision Resources. "While enthusiasm for agents with self-administration (e.g., Humira, UCB's Cimzia) may lead to slower growth for Remicade in the future, our survey results make it clear that physicians prescribe Remicade based on its perceived superior efficacy in inducing remission and in healing fistulizing forms of Crohn's disease compared with Humira and Cimzia."

The new Treatment Algorithms in Crohn's Disease report also finds that a major shift in U.S. gastroenterologists' prescribing patterns will occur over the next two years. More than 60 percent of U.S. surveyed gastroenterologists will increase their use of a top-down approach to treating Crohn's disease in newly diagnosed patients (i.e. starting with a biologic) and more than 70 percent will decrease their use of corticosteroids in newly diagnosed patients.

By combining patient-level claims data with physician survey data, this report can be used to build p
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
5. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
6. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
7. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
8. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... MIVI-TRUST Phase III Program, Confirming... -- LEUVEN, Belgium, September 6, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Medicine Technology:ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 2ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 3ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 4ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 5ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 6ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 7ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 8ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 9ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 10China Sky One Medical Updates Financial Guidance for 2010 2China Sky One Medical Updates Financial Guidance for 2010 3China Sky One Medical Updates Financial Guidance for 2010 4China Sky One Medical Updates Financial Guidance for 2010 5China Sky One Medical Updates Financial Guidance for 2010 6China Sky One Medical Updates Financial Guidance for 2010 7China Sky One Medical Updates Financial Guidance for 2010 8
(Date:12/24/2014)... Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, ... 2014, court documents indicate that 1,183 claims had been ... developed gynecomastia (male breast growth) and other complications allegedly ... that this represents an increase of more than 100 ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... December 25, 2014 Today, UWDress.com, the famous ... sleeve wedding gowns, and launched a site-wide wedding gown promotion. ... sleeve wedding gowns in a more unexpected way, the collection ... are popular in the global market, and they are available ... UWDress.com are offered at discounted prices, up to 75% off; ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company ... the company announces its multiple layer bamboo panel ... these new products. , Bamboo panel is the product ... layer bamboo panel board features high quality selective bamboo ... free. The bamboo panel consists of multiple layers of ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2
... be crumbling under the mounting pressure of dengue. Safdarjung ... several patients being referred to AIIMS and the Red ... patients are given platelets only on the condition of ... exchange for the required platelets. Dr Santosh at the ...
... come up with some valuable information which would definitely ... the mind of an autistic person is blue printed. ... to be affected by autism a developmental disorder typically ... people. ,Lead researcher Dr Michael Murias, from ...
... disorders in women may be diagnosed by examining hair ... It is usually difficult to diagnose eating disorders//, as ... they try to hide it. ,The study ... University (BYU) in U.S. is published in the Rapid ...
... has made a formal application to the European Medicines ... as a viable treatment// for advanced HER2-positive and hormone ... received from the international TAnDEM study which showed that ... from 2.4 months to 4.8 months. ,HER2-positive breast ...
... by NHS hospitals because they are serving meals that are ... catering at 97 health trusts. ,The survey revealed ... food brought in by relatives and friends. Over 37% of ... or tasted disgusting. ,Over a fifth of patients claimed that ...
... John Howard ,the prime minister of Australia, stirred up the ... media for the first time that she had battled ... the National Breast Cancer Centre, she was addressing an august ... all important national breast cancer report.,Over the ‘Pink Ribbon’ breakfast ...
Cached Medicine News:Health News:Mounting Pressure of Dengue in Delhi Hospitals 2Health News:Eating Disorders may be diagnosed by Hair analysis 2Health News:NHS Food Slowing Patient Recovery 2
... chemiluminescence assay for the measurement ... serum. Growth Hormone (GH) is ... the anterior pituitary gland under ... hormone releasing hormone (GHRH) and ...
... the sulfate ester of DHEA, derived from ... DHEA in adrenal and extradrenal tissues. DHEA ... the adrenal cortex, and is a precursor ... relatively weak androgenic activity, which for unsulfated ...
... The DHEA-S ELISA kit is based ... separation. An unknown amount of DHEA-S present ... of DHEA-S conjugated with horse-radish peroxidase compete ... DHEA-S antiserum coated onto the wells. After ...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: